An observational study in Primary Immune Deficiency Disorder, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by University of Zurich · Observational
The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of different diseases with susceptibility to infection and/or a deregulated inflammatory response, is poorly understood. Available treatments are often not specific for a distinct target and might be associated with side effects. To elucidate pathophysiology of different PIDs, stool, urine, blood, tissue biopsies and/or bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. In a second step, targeted treatment for different PIDs might be developed preclinically and ex vivo according to underlying pathophysiology.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
This study's planned enrollment of 300 is above the median of 137 across 77 observational studies indexed under Primary Immunodeficiency Diseases.
Browse Primary Immunodeficiency Diseases studies →University of Zurich is the lead sponsor of 1,049 studies on the registry; 133 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with PID and healthy controls of all ages might be tested, recruitment is in a tertiary care hospital setting
Inclusion Criteria:
Exclusion Criteria:
Patients with Primary Immunodeficiency
Diagnostic Test: Diagnostic Test
Healthy Controls
Diagnostic Test: Diagnostic Test
Characterisation of cellular and functional phenotype in different PIDs
Characterisation of cellular phenotype in different PIDs
Immune cell subsets will be analysed for Surface marker Expression or cell activation pathways
Time frame: immediately after sampling of biological specimen or up to 10 years later from frozen samples
Characterisation of functional phenotype in different PIDs
Immune cell subsets will be analysed for cytokine production or cell activation pathways
Time frame: immediately after sampling of biological specimen or up to 10 years later from frozen samples
Identification of potential targets for pathophysiology-specific treatment, or for curative treatment such as gene therapy for different PIDs ex vivo
Targets for development of new Treatment for PID identfied by Primary outcome analyses (see above) can be pathways, Surface marker Expression or cytokine production. Therefore new Treatment developed might consist of medication interfering with cell activation pathways, cytokine production (e.g. inhibitory antibodies against specific cytokines) or Surface marker Expression (e.g. inhibitory or stimulatory ligands for certain cell Surface receptors)
Time frame: immediately after sampling of biological specimen or up to 10 years later from frozen samples
Plan to share: Undecided — We are planning to share IPD in the form of Scientific publications in peer-reveiwed journals and communications at Scientific meetings
No publications or documents are linked to this record.
Started Mar 2015 (actual). Primary completion is estimated for Mar 2033, 216 months after the start.
Of 50 observational studies under Primary Immunodeficiency Diseases, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 30. This study's planned 216 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →